Abiraterone dose adjusted by blood levels versus standard dose in advanced prostate cancer
Compares standard abiraterone dosing with blood-level-guided dosing in men with advanced prostate cancer.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Comparison of standard abiraterone dosing and dosing based on abiraterone blood levels
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 230 people, planned
- Started
- 1 May 2026
- Expected to end
- 30 Apr 2035
- Type of study
- Interventional
- Record updated
- 28 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone therapy. It compares standard abiraterone dosing with dosing guided by blood levels of the drug.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Metastatic castration-resistant prostate cancer (mCRPC), confirmed by tissue or cell tests, with disease that can be measured by RECIST 1.1 before the first dose.
- Earlier treatment
- Can join if never had chemotherapy, or had one line of docetaxel-based chemotherapy in the HSPC or CRPC stage. Cannot join if previously treated with an androgen receptor signalling inhibitor such as abiraterone, enzalutamide or darolutamide.
Main reasons for not taking part
- Metastatic hormone sensitive prostate cancer (mHSPC)
- Previous treatment with abiraterone, enzalutamide, darolutamide or a similar drug
- Taking drugs that induce CYP3A4 (except dexamethasone) or drugs with severe QT prolonging effects within 14 days before admission
- Another serious illness that the study drug could make worse
- Any condition that could interfere with the study or make taking part an unacceptable risk, as judged by the investigator
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients with metastatic castration-resistant prostate cancer (mCRPC)
- Male ≥18 years old
- Histologically or cytology confirmed prostate cancer
- Patients can either be chemotherapy-naïve or have received one line of docetaxelbased chemotherapy in the HSPC or CRPC stage
- Measurable disease (by RECIST criteria version 1.1) prior to the first dose of study treatment
- Signed written Ethical Committee (EC) approved informed consent form, prior to performing any study-related procedures
Who cannot take part
- Patients who were previously treated with an androgen receptor signalling inhibitor (e.g. abiraterone, enzalutamide, darolutamide)
- Any significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug
- Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or absorption of oral medications, or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the participant in this study
- Patients with metastatic hormone sensitive prostate cancer (mHSPC)
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry
- Consumption of agents which induce CYP3A4 (with the exception of dexamethasone) or agents with severe QT prolonging effects within 14 days prior to admission and during the study (see concomitant medication restrictions)
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To compare radiographic PFS in the TDMguided dosing arm for the subgroup who had a Cmin < 8.4 ng/mL at a certain time point during treatment, to the patients in the fixed dosing arm who had a Cmin < 8.4 ng/mL at a certain time point during treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Standard dosed abiraterone versus Therapeutic Drug Monitoring guided abiraterone dosing – The Adapt Abi trial
- Plain-language title
- Abiraterone dose adjusted by blood levels versus standard dose in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 28 May 2026